Entrada Therapeutics (TRDA) Competitors $17.93 +0.16 (+0.90%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TRDA vs. AMRX, SRRK, ZLAB, JANX, CPRX, IOVA, TWST, LBPH, ARWR, and PTGXShould you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Amneal Pharmaceuticals (AMRX), Scholar Rock (SRRK), Zai Lab (ZLAB), Janux Therapeutics (JANX), Catalyst Pharmaceuticals (CPRX), Iovance Biotherapeutics (IOVA), Twist Bioscience (TWST), Longboard Pharmaceuticals (LBPH), Arrowhead Pharmaceuticals (ARWR), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Entrada Therapeutics vs. Amneal Pharmaceuticals Scholar Rock Zai Lab Janux Therapeutics Catalyst Pharmaceuticals Iovance Biotherapeutics Twist Bioscience Longboard Pharmaceuticals Arrowhead Pharmaceuticals Protagonist Therapeutics Amneal Pharmaceuticals (NASDAQ:AMRX) and Entrada Therapeutics (NASDAQ:TRDA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, community ranking, media sentiment, valuation, risk, analyst recommendations and institutional ownership. Is AMRX or TRDA more profitable? Entrada Therapeutics has a net margin of 25.53% compared to Amneal Pharmaceuticals' net margin of -6.88%. Entrada Therapeutics' return on equity of 16.11% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amneal Pharmaceuticals-6.88% -346.26% 4.85% Entrada Therapeutics 25.53%16.11%10.39% Does the MarketBeat Community believe in AMRX or TRDA? Entrada Therapeutics received 1 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 93.75% of users gave Amneal Pharmaceuticals an outperform vote while only 80.00% of users gave Entrada Therapeutics an outperform vote. CompanyUnderperformOutperformAmneal PharmaceuticalsOutperform Votes1593.75% Underperform Votes16.25%Entrada TherapeuticsOutperform Votes1680.00% Underperform Votes420.00% Do insiders & institutionals believe in AMRX or TRDA? 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 26.6% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 7.6% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend AMRX or TRDA? Amneal Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 18.91%. Entrada Therapeutics has a consensus price target of $24.00, indicating a potential upside of 33.85%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amneal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer AMRX or TRDA? In the previous week, Amneal Pharmaceuticals had 4 more articles in the media than Entrada Therapeutics. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 2 mentions for Entrada Therapeutics. Amneal Pharmaceuticals' average media sentiment score of 0.88 beat Entrada Therapeutics' score of -0.30 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, AMRX or TRDA? Amneal Pharmaceuticals has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.26, suggesting that its stock price is 126% less volatile than the S&P 500. Which has higher valuation and earnings, AMRX or TRDA? Entrada Therapeutics has lower revenue, but higher earnings than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmneal Pharmaceuticals$2.39B1.09-$83.99M-$0.68-12.37Entrada Therapeutics$129.01M5.20-$6.68M$1.5911.28 SummaryEntrada Therapeutics beats Amneal Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRDA vs. The Competition Export to ExcelMetricEntrada TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$664.95M$6.48B$5.06B$8.89BDividend YieldN/A8.11%4.97%4.06%P/E Ratio11.284.8389.0213.30Price / Sales5.20372.991,207.2881.01Price / CashN/A52.2739.1736.03Price / Book1.597.876.085.74Net Income-$6.68M$153.61M$119.07M$225.93M7 Day Performance-5.83%-2.00%-1.84%-1.32%1 Month Performance3.52%-7.47%-3.65%0.60%1 Year Performance7.56%31.80%31.62%26.23% Entrada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRDAEntrada Therapeutics1.9803 of 5 stars$17.93+0.9%$24.00+33.9%+9.9%$664.95M$129.01M11.28110AMRXAmneal Pharmaceuticals2.9437 of 5 stars$8.41-0.4%$10.00+18.9%+86.9%$2.61B$2.39B0.007,700Insider TradeSRRKScholar Rock4.1709 of 5 stars$27.86flat$34.00+22.0%+137.1%$2.61B$33.19M-11.86140ZLABZai Lab2.9574 of 5 stars$26.23+0.3%$52.50+100.2%-7.2%$2.60B$266.72M-9.472,175Analyst RevisionJANXJanux Therapeutics3.5908 of 5 stars$48.96-0.1%$66.44+35.7%+441.0%$2.57B$8.08M0.0030CPRXCatalyst Pharmaceuticals4.7417 of 5 stars$21.15-1.1%$31.14+47.2%+54.3%$2.55B$398.20M17.92167Analyst ForecastIOVAIovance Biotherapeutics4.0475 of 5 stars$8.14-0.6%$22.33+174.4%+48.3%$2.50B$1.19M0.00500Options VolumeTWSTTwist Bioscience4.1398 of 5 stars$41.11-0.5%$51.78+25.9%+66.2%$2.45B$312.97M-11.42990Analyst ForecastAnalyst RevisionLBPHLongboard Pharmaceuticals1.4685 of 5 stars$59.77-0.1%$59.56-0.4%+1,283.6%$2.34BN/A0.0020ARWRArrowhead Pharmaceuticals3.5698 of 5 stars$18.71+0.6%$45.33+142.3%-35.3%$2.31B$240.74M0.00400Upcoming EarningsAnalyst ForecastPTGXProtagonist Therapeutics3.0192 of 5 stars$40.65+5.2%$53.57+31.8%+135.8%$2.30B$60M15.28125Analyst ForecastNews Coverage Related Companies and Tools Related Companies Amneal Pharmaceuticals Alternatives Scholar Rock Alternatives Zai Lab Alternatives Janux Therapeutics Alternatives Catalyst Pharmaceuticals Alternatives Iovance Biotherapeutics Alternatives Twist Bioscience Alternatives Longboard Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives Protagonist Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRDA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRDA Stock Alerts